This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1988 Aug 15;48(16):4441-54.

Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review

J L Grem¹, S A King, P J O'Dwyer, B Leyland-Jones

Affiliations

PMID: 3293772

Review

Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review

J L Grem et al. Cancer Res. 1988.

. 1988 Aug 15;48(16):4441-54.

Authors

J L Grem¹, S A King, P J O'Dwyer, B Leyland-Jones

Affiliation

¹ Investigational Drug Branch, National Cancer Institute, Bethesda, Maryland 20892.

PMID: 3293772

No abstract available

PubMed Disclaimer

Similar articles

Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS, Gralla RJ, Kemeny NE. Carroll DS, et al. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):349-51. Cancer Treat Rep. 1980. PMID: 7407769 No abstract available.
Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES, Gralla RJ, Kelsen DP, Houghton A, Golbey RB, Young CW. Casper ES, et al. Cancer Treat Rep. 1980 Apr-May;64(4-5):705-7. Cancer Treat Rep. 1980. PMID: 6448688 No abstract available.
An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C. Erlichman C. Recent Results Cancer Res. 1980;74:65-71. doi: 10.1007/978-3-642-81488-4_9. Recent Results Cancer Res. 1980. PMID: 7444150
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Martin DS, Stolfi RL, Sawyer RC, Young CW. Martin DS, et al. Cancer Treat Rep. 1985 Apr;69(4):421-3. Cancer Treat Rep. 1985. PMID: 3888389 Review. No abstract available.
m-AMSA and PALA: two new agents in cancer chemotherapy.
Rozencweig M, Von Hoff DD, Cysyk RL, Muggia FM. Rozencweig M, et al. Cancer Chemother Pharmacol. 1979;3(3):135-41. doi: 10.1007/BF00262414. Cancer Chemother Pharmacol. 1979. PMID: 393427 Review.

See all similar articles

Cited by

In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Peters GJ, Kraal I, Pinedo HM. Peters GJ, et al. Br J Cancer. 1992 Feb;65(2):229-33. doi: 10.1038/bjc.1992.46. Br J Cancer. 1992. PMID: 1739622 Free PMC article.
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Hageboutros A, Hudes GR, Brennan J, Green F, Hoffman J, LaCreta FP, Colofiore J, Martin DS, Ozols RF, O'Dwyer PJ. Hageboutros A, et al. Cancer Chemother Pharmacol. 1996;37(3):229-34. doi: 10.1007/BF00688321. Cancer Chemother Pharmacol. 1996. PMID: 8529282 Clinical Trial.
An adipo-biliary-uridine axis that regulates energy homeostasis.
Deng Y, Wang ZV, Gordillo R, An Y, Zhang C, Liang Q, Yoshino J, Cautivo KM, De Brabander J, Elmquist JK, Horton JD, Hill JA, Klein S, Scherer PE. Deng Y, et al. Science. 2017 Mar 17;355(6330):eaaf5375. doi: 10.1126/science.aaf5375. Epub 2017 Mar 16. Science. 2017. PMID: 28302796 Free PMC article.
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Martino RL, Fleming TR, Morrell LM, Ardalan B, Richman SP, Macdonald JS. Martino RL, et al. Invest New Drugs. 1996;14(4):419-21. doi: 10.1007/BF00180821. Invest New Drugs. 1996. PMID: 9157080 Clinical Trial.
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Horber DH, Schott H, Schwendener RA. Horber DH, et al. Cancer Chemother Pharmacol. 1995;36(6):483-92. doi: 10.1007/BF00685798. Cancer Chemother Pharmacol. 1995. PMID: 7554040

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database